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increasing per pack taxes by at least 10%, but smokers’ lives were slightly extended 
by the ban condition. Incremental cost effectiveness ratios for taxes and bans, relative 
to no intervention were: $29,827 and $29,814 per life year gained, respectively.
CONCLUSIONS: Both public policy strategies of taxes and bans have a minimal 
impact on life years gained over the lifetimes of smokers. Taxes showed an advantage 
in lower hospitalization and value of lives saved. In addition, taxes are revenue enhanc-
ing, while bans require additional enforcement resources. Using tobacco taxes to 
reduce tobacco consumption and subsequent tobacco-related disease is superior to
smoking bans, though the combination of the two policies may be mutually reinforcing
for behavioral change and additive in effect.
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COST EFFECTIVENESS OF CLOPIDOGREL TREATMENT VERSUS ASPIRIN 
TREATMENT IN SOUTH KOREAN PATIENTS WITH ATHEROTHROBOSIS: 
RESULTS OF THE CAPRIE (CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS
AT RISK OF ISCHEMIC EVENTS) STUDY
Yang BM, Shin S, Lee JH
Seoul National University, Seoul, South Korea
OBJECTIVES: Clopidogrel is a frequently used drug to prevent subsequent
atherothrombotic events in patients with stroke, myocardial infarction, or peripheral
arterial diseases. Doctors should subjectively determine whether the price of clopido-
grel is justiﬁ ed by its improved therapeutic effect compared to that of aspirin, consider-
ing country-wise economic situation. This study analyzed the cost-effectiveness
of clopidogrel for atherothrombosis treatment in South Korea. METHODS: Cost-
effectiveness was analyzed using the Cambridge model; a Markov model developed
using data from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic 
Events (CAPRIE) study, as per Korean situation. The effect was estimated using
data from the Framingham and Saskatchewan databases to calculate the expected
survival (in years) for various health states. Direct medical costs from the social 
perspective, direct non-medical costs, and indirect medical costs were analyzed;
applying 5% discount rate to both cost and effect. RESULTS: The 2-year follow-up 
results showed that the number of cardiovascular (CV) events and CV deaths per
1000 patients was decreased by 13.19 and 2.21, respectively, in the clopidogrel
group as compared to the aspirin group. As clopidogrel treatment decreased the inci-
dence of CV deaths; the number of life-years gained per 1000 patients was 65.65
(Framingham) and 48.20 (Saskatchewan). The incremental cost-effectiveness ratio 
determined using incremental costs per life-year gained was US$ 19,017 (Framingham) 
and US$ 25,904 (Saskatchewan). CONCLUSIONS: Our results showed that clopido-
grel was cost-effective treatment of atherothrombosis in South Korea, and evaluated 
a basis for the economic feasibility of clopidogrel administration for atherothrombosis 
treatment.
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OBJECTIVES: Syncope is a signiﬁ cant burden on the health care system and individu-
als. Screening manoeuvres including medical examination, ambulatory external moni-
toring, imaging and clinical diagnostic tests provide a presumptive diagnosis in a 
limited number of patients since syncope recurrence is unpredictable. Establishing or 
ruling out a cardiac arrhythmia as the cause is challenging, time consuming and relies 
on recording the cardiac rhythm at the time of spontaneous recurrences. The Insertable
Cardiac Monitor(ICM) is a new, efﬁ cient and accurate technique for long-term
monitoring and recording the “events” in a patient. This study assesses the cost-
effectiveness of adding the ICM to the standard diagnostic protocol in Canadian
health care system. METHODS: A decision analytic model was developed assessing 
the cost-effectiveness of the standard diagnosis approach compared to ICM from 
a Canadian provider perspective. The main clinical outcome used in the model
was “yield” deﬁ ned as the rate of correct diagnoses derived from published literature.
The frequency of resources used and associated costs were derived from literature
and the Ontario Health Insurance Policy. RESULTS: The diagnosis yield for ICM
and standard approach was 33.7% and 4.1% respectively. The model assessed
the cost per diagnosis in the two arms. The incremental cost per diagnosis was $6237 
in favour of ICM. Sensitivity analysis showed that in the lower conﬁ dence interval 
(CI) the ICM is the “dominant” option and in upper CI limits the ICER was $35,358
and below the $50,000 acceptability threshold. CONCLUSIONS: ICM is a safe,
accurate and effective device for diagnosis of syncope and should be considered as
an alternative in diagnosis of syncope. The cost of ICM is partially offset by savings 
in hospitalization. A societal perspective will reduce the ICER in favour of ICM by 
preventing complications of syncope (i.e., falls, fractures, mortality) and increase
patient HRQoL.
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OBJECTIVES: To determine the cost-effectiveness, from the Brazilian Ministry of 
Health perspective, of Fluvastatin IR 20 mg, Fluvastatin IR 40 mg, Fluvastatin IR
80 mg and Fluvastatin XL 80. Also we calculated the budget impact of introducing
Fluvastatin XL 80 mg into the current Brazilian national drug formulary. METHODS:
The cost effectiveness was determined using clinical data from published systematic
review and cost the costs were valued using government prices. The costs was in Brazil-
ian reais (BRL) and the price year was 2008 (1$US  1.63 BRL). The beneﬁ t measure
used in this economic evaluation was LDL- reduction. Using the Healtchare System
database’ data we described the evolution of consumption of statins in Brazilian
Health System. Univariate sensitivity analysis tested model robustness. We calculated 
the budget impact analysis for three years. RESULTS: The Fluvastatin XL 80 mg is
the statin more cost-effective and permits the cost reduction in BRL $26,10 per patient.
The sensitivity analysis of budget impact show that introduction Fluvastatin into for-
mulary could generate average savings of 18% of the Fluvastatin’s total budget or 
BRL 56,500 ($US 34,600). CONCLUSIONS: The inclusion of Fluvastatin XL 80 mg 
is aligned with the health authority strategy of cost containment or reduction for this 
class of medicines. Results are sensitive to the list price of drugs.
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OBJECTIVES: Existing triage strategy is suboptimal in risk stratifying Asian 
patients with chest pain. Hence, we aim to determine the cost-effectiveness of an add-
on stress myocardial perfusion imaging (MPI) in improving risk stratiﬁ cation in a 
single-centre randomized controlled trial involving Asian patients with chest pain and 
non-diagnostic ECG presenting to an emergency department (ED) in Singapore. 
METHODS: Consenting patients were randomly assigned to with or without MPI 
add-on. Patients who developed ST segment changes, elevated CKMB/ Troponin 
during the 6-hr observation were admitted without receiving the assigned interven-
tions. One-year cost-effectiveness of the two strategies (MPI vs. no MPI) was analysed
from the institution’s perspective. Inpatient costs were obtained from electronic data-
base. Outpatient costs were estimated with expert input. Effectiveness was measured
as percent patients accurately risk stratiﬁ ed at one year (i.e. high/medium risk patients 
experiencing a cardiac event and low risk patients not experiencing any cardiac event
within one year). The incremental cost-effectiveness ratio (ICER) and conﬁ dence
intervals (CI) were constructed by bootstrap analysis (percentile approach). Sensitivity 
analysis was conducted for outpatient costs. RESULTS: Cost data were available from
1418 patients (83.9% of randomized patients). The ICER of MPI vs. no MPI was
$6,334 ($13,474 to $40). 97.6% of bootstrapped replicates fell below the $0 per
accurate risk stratiﬁ cation level, indicating that the scan strategy dominated the no 
scan strategy. All bootstrap replicates fell in the north- and south-east quadrants on
the cost-effectiveness plane, conﬁ rming that the negative ICER was due only to nega-
tive cost differences. Coefﬁ cient of variation (CV) of the effect difference is 0.19. Small 
bias to standard error ratio (0.013) justiﬁ es not making bias correction in estimating 
CI. Results were insensitive to outpatient costs. CONCLUSIONS: Add-on MPI is 
cost-effective in risk stratifying patients with chest pain. Given the small CV, bootstrap
estimates are likely to be robust.
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DECISIONS FOR ENHANCED EXTERNAL COUNTERPULSATION IN 
ANGINA
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OBJECTIVES: To demonstrate how expert elicitation can be combined with Bayesian 
decision theory to inform the decision to conduct further research and identify efﬁ cient
research design when there is limited evidence available. METHODS: Using a model 
of enhanced external counterpulsation (EECP) for the treatment of angina, expert 
elicitation was used to provide informed priors on the key model parameters where 
no evidence was available. These priors were updated with sample information to 
quantify the expected value of sample information (EVSI). The EVSI was compared 
to the costs of sampling and the expected net beneﬁ t of sample information was
obtained (ENBS). The ENBS is a measure of the societal payoff to research and pro-
vides a sufﬁ cient condition for deciding to conduct more research. Given the need to
establish if EECP has a role for treating angina and the paucity of effectiveness 
evidence available, the ENBS was used to determine the type of study required, 
the optimal sample size, the appropriate length of follow-up and the endpoints 
that should be included. RESULTS: There is signiﬁ cant value to future research 
in EECP. This research is most valuable when directed towards establishing the
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short- and longer-term effectiveness of EECP. Although the ENBS depends on the 
cost-effectiveness threshold, the ENBS is positive for most sample sizes indicating that 
further experimental research will be efﬁ cient. A clinical trial design is proposed with 
equal allocation of patients between arms. Given a threshold of a20,000 per QALY 
gained, the highest expected returns to additional research will come from a trial with
a 4-year follow-up and an optimal sample size of 900. CONCLUSIONS: Expert elici-
tation and value of sample information can be combined into a single coherent 
framework to establish the value of further research, the optimal design of such
research, and the most appropriate basis for informing cost-effectiveness.
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ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN FOR THE NON-
INVASIVE MANAGEMENT OF PATIENTS WITH NON-ST-SEGMENT
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OBJECTIVES: To compare one-day cost efﬁ cacy and safety of enoxaparin 1 mg/kg
subcutaneous injection twice daily with unfractionated heparin intravenous infusion 
for the conservative management in patients with NSTE-ACS. METHODS: Eighty
patients were enrolled in the study and received enoxaparin 10 mg/kg subcutaneous 
injection twice daily (n  40) or unfractionated heparin intravenous infusion (n  40) 
for the conservative management in patients with NSTE-ACS. Treatment efﬁ cacy was
evaluated on the basis of the combination of clinical, ECG and laboratory indexes. 
The therapy was considered to be non-effective in case of death, nonfatal myocardial 
infarction (MI), early angiography with subsequent revascularization and major bleed-
ing. RESULTS: Total expenses per 1 patient (only direct costs) and cost/efﬁ cacy ratio
were calculated for each anticoagulant group. The following cases were recorded in 
unfractionated heparin group: one death, two major bleedings, and ﬁ ve MIs. Treat-
ment efﬁ cacy proved to be 80% while total expenses per 1 patient stood at 46,489
rubles and cost/efﬁ cacy ratio accounted for 58,111 rubles per every effective treatment
(current exchange rate 1$  29 rubles). Enoxaparin showed 3 MIs and 1 performed
acute angioplasty. Treatment efﬁ cacy was 90% while total expenses per 1 patient was 
46,993 rubles and cost/efﬁ cacy ratio was 52 214 rubles per 1 effective treatment. After
compare the costs of treatment and its efﬁ cacy in both groups enoxaparin proved to 
be the most cost-effective anticoagulant due to the smallest total expenses and cost/
efﬁ cacy ratio. CONCLUSIONS: Medical treatment with enoxaparin 1 mg/kg twice
daily in patients with NSTE-ACS proved to be more beneﬁ cial in terms of cost and 
efﬁ cacy than permanent intravenous infusion of unfractionated heparin.
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OBJECTIVES: Updated consensus guidelines published by the American College of 
Chest Physicians, and the International Union of Angiology recommend thrombopro-
phylaxis with either low-molecular-weight heparin or unfractionated heparin(UFH) in
medical patients at risk of VTE. The purpose of this study was to estimate the cost-
effectiveness of different thromboprophylactic agents to prevent or treat VTE associ-
ated with patients undergoing general surgery from the institutional perspective. 
METHODS: A six-state Markov model was performed to estimate health and eco-
nomic consequences during a time horizon of one year (1-week cycles). Effectiveness
measures were decreased number of deep vein thrombosis(DVT) and pulmonary 
thromboembolism(PE) events; reduction of recurrent hospitalizations and avoidance
of death. Transition probabilities were obtained from a meta-analysis employing inter-
national published literature. Comparators used in the assessment were warfarin(5 mg/
day); dalteparin(2,500,5,000,7,500 IU/day); acenocoumarol(4 mg/day); enoxaparin 
(20,40,60 mg/day); nadroparin(57,00 IU/day); UFH plus warfarin(10,000,30,000,42,
000 IU/day5 mg/day) and fondaparinux(2.5–7.5 mg/day). Resource use and costs 
were obtained from 8000 randomized hospital records from the Social Security 
Mexican Institute (IMSS) and ofﬁ cial institutional databases. Costs include outpatient
and inpatient services, drug, procedures, etc. The model was validated according to 
international guidelines. Probabilistic sensitivity analyses were performed employing 
bootstrapping techniques. Acceptability curves were constructed. RESULTS: Daltepa-
rin showed the lowest incidence of PE, DVT, thrombosis associated deaths and hospital
recurrence compared to the rest of thromboprophylactic therapies(p  0.05). Only
warfarin and acenocoumarol obtained costs below dalteparin strategy. Regarding the 
reduction of DVT events, dalteparin 2500, 5000 and 7000 IU/day show an ICER
[CI95%] of US$110.0[US$107.7–US$112.3]; US$101.3[US$99.1–US$103.5] and 
US$97.3[US$93.8–US$97.9] against warfarin (gold-standard), respectively. Enoxapa-
rin 20,40,60 mg/day; nadroparin and UHFwarfarin were dominated by dalteparin. 
Second-order Monte Carlo analysis showed that dalteparin could be a cost-saving 
treatment against enoxaparin with a probability over 50%. Component analyses 
further validated these results. CONCLUSIONS: Dalteparin is a cost-effective throm-
boprophylactic therapy to reduce PE and DVT events in Mexican medical patients at 
risk of VTE due its higher efﬁ cacy and lower cost.
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OBJECTIVES: A high risk to develop pulmonary thromboembolism (PE) and deep 
vein thrombosis (DVT) has been associated with certain surgeries and prolonged hos-
pitalization. The aim of this study was to assess the cost-effectiveness of different
anticoagulant therapies to prevent or treat VTE associated with hip surgery from 
the health care payer’s perspective. METHODS: A six-state stochastic Markov model 
was performed to estimate costs and effectiveness during a time horizon of one-year 
(1-week cycles). Effectiveness measures were reduction in PE and DVT events; 
decreased hospitalizations and avoidance of death. Transition probabilities were 
obtained from a meta-analysis involving national and international published litera-
ture. Comparators used in the assessment were warfarin(5 mg/day); dalteparin
(2500,5000,7500 IU/day); acenocoumarol(4 mg/day); enoxaparin(20,40,60 mg/day); 
nadroparin(5700 IU/day); unfractionated heparin plus warfarin(10000,30000,42000 
IU/day5 mg/day) and fondaparinux(2.5–7.5 mg/day). Resource use and costs were 
obtained from hospital records (n  8000) from the Social Security Mexican Institute
(IMSS) and ofﬁ cial institutional databases. Costs include outpatient and inpatient 
services, drug, procedures, etc. The model was validated according to international 
guidelines. Sensitivity analyses were performed employing bootstrapping techniques 
and acceptability curves were constructed. RESULTS: Incidence of PE and DVT were 
signiﬁ cantly lower in patients receiving dalteparin treatment (p  0.05). Regarding
the reduction of DVT events, dalteparin 2500, 5000 and 7000 IU/day showed
an ICER[CI95%] of US$214.02[US$209.47–US$218.58]; US$198.65[US$194.43–
US$202.89] and US$189.06[US$185.04–US$193.09] against warfarin, respectively.
Dalteparin showed the lowest number of deaths and hospital re-admissions when
compared to other anticoagulant treatments(p  0.05) reducing signiﬁ cant costs in the 
short term within an institutional Mexican setting. Second-order Monte Carlo analy-
ses showed evidence that dalteparin would be more cost-effective than enoxaparin in 
a range of 60%–70%(p  0.05). CONCLUSIONS: In Mexico, dalteparin demon-
strated to be a cost-effective anticoagulant therapy to reduce the incidence of PE and
DVT, and avoid death and hospital re-admissions in the management of adult patients
after total hip replacement. These results should be taken into account by Mexican 
health professionals to generate cost-containment strategies.
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OBJECTIVES: Patients treated with total knee arthroplasty are at high risk for the 
development of venous thromboembolism postoperatively resulting in poor health
outcomes and generating additional costs to the health care system. The purpose of 
this study was to estimate the cost-effectiveness of different thromboprophylactic
agents to prevent VTE associated with knee surgery from an institutional perspective.
METHODS: A six-state stochastic Markov model was constructed to simulate health
and economic outcomes during a time horizon of one year (1-week cycles). Effective-
ness measures were prevention of events of deep vein thrombosis (DVT) and pulmonary 
thromboembolism(PE); and reduction of recurrent hospitalizations and deaths.
Markov transition probabilities were obtained from a meta-analysis employing 
international published literature. Comparators employed were warfarin(5 mg/day); 
dalteparin(2,500,5,000,7,500 IU/day); enoxaparin (20,40,60 mg/day); nadroparin
(57,00 IU/day); unfractionated heparin(UFH) plus warfarin(10,000,30,000,42,000 IU/
day5 mg/day); fondaparinux(2.5–7.5 mg/day) and no prophylaxis intervention.
Resource use and costs were collected from clinical records (n  7000) from Social
Security Mexican Institute(IMSS) hospitals. Costs include outpatient and inpatient 
services, drug, procedures, etc. The model was calibrated according to international 
guidelines. Probabilistic sensitivity analyses were performed employing bootstrapping
techniques and acceptability curves were constructed. RESULTS: Incidence of PE 
and related deaths were signiﬁ cantly lower for patients treated with dalteparin
(p  0.05). Regarding the prevention of PE events, dalteparin 2500, 5000 and 7000 IU/
day showed an ICER[CI95%] of US$1932.88[US$1,888.67–US$1977.11];
US$1800.87[US$1759.67–US$1842.07] and US$1718.52[US$1679.21–US$1757.84]; 
against warfarin(gold-standard), respectively. In addition, UFH yielded an ICER of 
US$23.35[US$22.82–US$23.89] and fondaparinux of US$1410.74[US$1378.47–
US$1,443.02]. However, enoxaparin, nadroparin, and no prophylaxis alternatives 
were dominated. Second-order Monte Carlo sensitivity analyses demonstrated a trend
that dalteparin would be more cost-effective than enoxaparin in a range of 50%–
60%(p  0.05) in PE events avoided. CONCLUSIONS: At IMSS, dalteparin compared 
to warfarin would be a cost-effective thromboprophylactic therapy to reduce risk
of PE and DVT events associated with total knee arthroplasty and showed 75% 
less related deaths than enoxaparin. These results could be useful for future cost-
containment policies.
